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Abstract
Background: Post kala azar dermal leishmaniasis (PKDL) is a disease that appears after treatment of
visceral leishmaniasis (VL). The highest incidence of PKDL in the world is in Sudan. Many patients heal
spontaneously within 6 months but those who don't are difficult to treat, often requiring months of daily
injections. These patients harbour parasite in their skin and are believed to be a source of infection and
possibly epidemics. Present treatment modalities of PKDL are inadequate and impractical due to cost,
duration of treatment required and side effects. New approach for treatment of PKDL is required. A joint
meeting of the UNICEF/UNDP/World Bank/WHO Special Programme for research and training in
Tropical Disease (TDR) and the Infectious Disease Research Institute (IDRI) Seattle, USA was held to
review the progress of therapeutic vaccines and plan the development of treatment modalities for PKDL.
Methods: The history of leishmaniasis vaccine development for prophylaxis and therapy was reviewed.
Other than previous infection – simulated by inoculation of live Leishmania as a vaccine (leishmanization),
none of the preparations of killed parasite with or without adjuvants have shown significant prophylactic
efficacy. Killed L. major absorbed with alum and mixed with BCG remains to be tested as a prophylactic
vaccine.
Results: Killed parasite preparations i.e. L. mexicana mixed with BCG and L. amazonensis (combined with
low dose of antimonial), have shown efficacy in immunotherapy and immuno-chemotherapy, respectively.
In addition combined full antimonial plus alum-absorbed autoclaved L. major vaccine has been shown to
significantly improve therapy of refractory PKDL patients. These are all crude preparations of parasites
and are difficult to define and standardize. However, there is now a new, second generation vaccine, Leish-
111f + MPL-SE, composed of a recombinant protein comprising three leishmanial antigens and a defined
adjuvant in clinical development.
Conclusion and recommendations: Immuno-chemotherapy has the potential of becoming a practical
and affordable treatment modality for PKDL and other forms of leishmaniasis. The encouraging results
with alum-autoclaved L. major + antimonial should be pursued. However, before further trials, availability
of the vaccine and its production under Good Manufacturing Product, hence quality control must be
assured. Following satisfactory safety profile of Leish-111f+MPL-SE, clinical trials using this vaccine initially
with antimonials should be initiated. Similarly immunotherapy of VL should be considered with the view
to controlling development of PKDL. Some immunological studies are required prior to initiation of
immunotherapy in VL patients.
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Background
Dr R. Ridley, Director of TDR, opened the meeting and
pointed out the importance of immunological interven-
tions for treatment of diseases. The therapeutic potential
of vaccines is easier to assess than the prophylactic efficacy
(quicker readout, smaller sample size, etc.) and may be
used as a screening mechanism to select candidate vac-
cines for prophylaxis, in this case against different forms
of leishmaniasis. Dr Ridley noted the initiative of the min-
istries of health of India, Nepal and Bangladesh to elimi-
nate leishmaniasis (as a public health problem) by 2015.
Clearly several tools will need to be added to the new
drugs and diagnostic tests recently developed and now
being evaluated. In addition, better treatment modalities
for VL and a practical treatment for PKDL would be highly
valuable.
Dr J. Lazdins, Coordinator PDE, indicated that use of
immuno-chemotherapy for increasing the efficacy of
medication and preventing an increase in drug-resistant
organisms is a logical approach. He was particularly inter-
ested in the recommendations from this meeting in con-
nection with consideration of combined therapy for other
TDR target diseases.
Dr Ghalib, Coordinator of Leishmaniasis Research (TDR),
presented the strategic research emphases of TDR for
2006–2007 and indicated that the shaping factors would
be publication of the Tri-Tryp genome and setting up of
the control initiative in South Asia. The first is a 'research
pull' to provide a wealth of information useful for devel-
opment of new tools. The second is a 'control pull' which
demands new tools and comprehensive efforts toward
controlling VL in South Asia. These are opportunities to be
seized.
Dr Ghalib noted that new effective drugs have appeared
(Miltefosine, Aminosidine, Ambisome) hoping that they
will become more affordable. However, he warned that
these are being used as single drug therapy. Use of com-
bined therapy including immuno-chemotherapy is
urgently needed to safeguard the new drugs against resist-
ance.
Dr Ghalib discussed the new tools on the horizon, includ-
ing a new erythrocyte binding assay based on chemical
changes to the surface of red blood cells during active VL
disease, which was developed by Dr. Mandal at the Indian
Institute of Chemical Biology and has been adapted into
a dipstick format. Evaluation of the rK39 dipstick test,
direct agglutination test (DAT), and latex agglutination
urine test has now been completed in Ethiopia, Kenya and
Sudan. The results from these sites are being analysed. Dr
Ghalib indicated that the purpose of the present consult-
ative meeting was to review progress and available tools,
and to recommend how to proceed towards developing
practical and affordable immunotherapeutic modalities
for treatment as well as prevention of PKDL.
Dr. Ghalib introduced to the participants the various
forms of leishmaniasis and their public health signifi-
cance in the world. The overall prevalence is estimated by
WHO to be 12 million with 350 million at risk. Ninety
five per cent of VL cases occur in five countries (India,
Bangladesh, Nepal, Sudan, and Brazil) and 90% of CL
cases occur in eight countries (Afghanistan, Algeria, Brazil,
Iran, Iraq, Peru, Saudi Arabia, Syria). There are about 20
Leishmania  species that cause disease in humans and
about 30 species of sandfly vectors. Based on the complex-
ity of the different epidemiological settings and the super-
imposed problem of co-infection with HIV in some parts
of the world, it is no surprise that the conventional tools
have failed to control leishmaniasis. New tools and better
use of available tools are needed. Recent endeavours have
been undertaken and new data accumulated on the use of
vaccines both for prevention and therapeutic use. Prophy-
lactic vaccines for leishmaniasis are being planned under
the Initiative for Vaccines Research (IVR) at WHO, while
immunotherapeutic vaccines for PKDL, VL, and VL-HIV
are the topics of interest to TDR. At present the vaccines
shown to be effective in protecting animals are: a whole
killed parasite +/- adjuvants (first generation vaccine); a
purified or recombinant vaccine (protein or DNA) plus
adjuvant; a live attenuated Leishmania; and a live virulent
L. major. Below we will consider those vaccines that have
entered clinical development for human use. Hence
experts with experience in human leishmaniasis vaccines
were convened for this meeting in order to review the
available data and recommend avenues to be explored in
developing a safe, efficacious and affordable vaccine, with
a focus on immunotherapy of VL and PKDL.
Presentations
Please see Additional file 1 for list and addresses of all
contributors.
Professor Zijlstra, Chairperson of the meeting, described
the epidemiology of CL and VL [1] and the natural history
of VL with ensuing PKDL in Sudan [2]. Whereas PKDL
develops in 50%–60% of VL cases in Sudan, the incidence
of reported PKDL cases remains at about 0.8%–8% in
India.
Inadequate treatment may be a factor in the development
of PKDL; however, even with complete treatment to cure,
PKDL may develop [3]. Other factors such as genetics, the
organism, nutrition, etc., may be important. Presentation
of PKDL is diverse, may develop in a few cases without
previous obvious VL, and can involve other post kala azar
manifestations in oral, ocular and nasal tissues. In chil-Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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dren, severity is inversely related to age; the majority of
patients with grade 3 severity are generally children less
than 8 years old. Response to treatment does not seem to
be associated with severity, and the majority of cases self
heal. About 40%–45% of cases in Sudan do not cure
spontaneously within 6 months and about 20% still have
PKDL after a year [3]. PKDL patients require several
months of treatment with daily injections of antimony.
This is not affordable or practical for patients. As it is well
known to the local populations that PKDL, unlike VL, is
not life-threatening, people take it as a good sign, believ-
ing that the deadly disease has surfaced and will not be
able to kill. Treatment is therefore not sought. The role of
PKDL as a reservoir has not been directly proven in Sudan
(but is well documented in India); however PKDL
patients do harbour parasites in their skin [4]. Therefore
treatment of PKDL should be considered as an important
public health measure for controlling VL.
Professor EAG Khalil presented immunopathology and
chemotherapy of VL and PKDL in Sudan. He described the
wide range of disease manifestations from localized skin
lesion (leishmanioma) to severe cutaneous disfiguration
by PKDL, even uveitis and blindness, psychological and
nervous system involvement. He indicated that in severe
VL no organ is spared, and discussed VL-associated patho-
logical manifestations in different organs including lym-
phadenopathy, splenomegaly, hepatomegaly, immune-
complex associated glomerulonephritis, pneumonia and
tuberculosis. He contrasted the polarized Th1–Th2
responses of the mouse with those in human leishmania-
sis, in which the two responses overlap, and indicated that
genetic factors, nutrition and the amount of antigen may
determine the type of response. Both Th1 and Th2 antigen
specific cells are present in cured VL patients. Neverthe-
less, during active disease, interleukin-10 (IL-10) levels
increase in lymph node cells and peripheral blood mono-
nuclear cells (PBMC) [5]. Addition of IL-10 inhibits pro-
liferation of PBMC from cured patients to leishmanial
antigens. The balance between Th-1/Th-2 responses in
progression of disease (Th2 predominance) and cure (Th1
predominance) was stressed.
Professor S. Sundar reviewed different treatment modali-
ties of VL in India. The efficacy of first-line drugs (pentav-
alent antimonials) had dropped from 84% in 1988 to less
than 40% in 2002 [6]. A similar trend is being seen in
Nepal. The rate of drug-related deaths, primarily due to
cardiotoxicity, is 3%–5%. Pentamidine, used as second-
line drug for years, is not being used due to toxicity.
Amphotericin B is used only in hospitals due to its toxic-
ity, and its use is limited because most patients cannot
afford it. Lipid-associated amphotericin B has limited tox-
icity due to lower doses being efficacious, and because
there is less circulating drug as the lipid complex is taken
up preferentially by the reticuloendothelial system [7,8].
Ambisome, the best drug available, which can cure about
90% of VL cases with a single injection, is far too expen-
sive [7].
Recent work on the new (the first) oral drug for VL, Milte-
fosine, was presented. Using 100 mg/day for patients over
25 kg body weight (or 2.5 mg/kg for children) for four
weeks, the initial cure rate was very high (98%) with mod-
erate and acceptable side effects. Hospitalization is not
required, which reduces the cost of treatment considera-
bly. However, with home-based treatment lasting for four
weeks, compliance is likely to be low when a patient feels
well after 1–2 weeks of treatment unless a DOT-like treat-
ment system is implemented. In a recent home-based trial
on 367 patients, a relapse rate of 6.7% was observed,
which might be the result of lower compliance compared
to the original hospital-based trial. The present cost is also
a concern. In addition, miltefosine is teratogenic in ani-
mals, hence should not be given to women of childbear-
ing age without adequate contraception.
Aminosidine (paromomycin) is a more affordable drug
with few side effects. In a phase-III comparative trial with
Amphotericin B, 95% cure was achieved with 21 daily
injections of Aminosidine (15 mg/kg/day) assessed after 6
months. This represented comparable efficacy but with far
fewer side effects than Amphotericin B. Aminosidine is
less costly and would be a good replacement for antimo-
nials.
Sitamaquine (WR6026), an oral drug originally discov-
ered by the Walter Reed Army Institute of Research, was
initially tested in a limited number of patients in Kenya. A
phase-II dose finding trial indicated 80%–100% cure
rates. Further studies are planned.
Prof. Sundar summarized the therapeutic options for
India as shown below and emphasized that, to prevent
development/escalation of drug failure, it is recom-
mended that combination therapy (drugs or drug + vac-
cine) be developed.
Summary of therapeutic options
• Use antimony only in responsive regions.
• Amphotericin B is the most important drug available
and gives >95% cure rate. As Ambisome is extremely
expensive, Amphotericin B or a new formulation of stable
lipid-Amphotericin B at affordable price is needed.
• Miltefosine (oral):
- effective and safeKinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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- price should be reduced to affordable levels, even in the
private sector
- is teratogenic in animals, with a long half life (rapid
emergence of resistance)
- is costly and not affordable (Rs 6600.00, about US$
1480)
- is there compliance with domiciliary care (DOT)?
• Paromomycin
- are quite promising, and an appropriate substitute for
antimony.
• A combination of drugs (to achieve a short treatment
regimen) is required.
First generation vaccines
Professor F. Modabber reviewed the global experience
with first generation vaccines (whole parasites with or
without BCG as adjuvant) used for prophylaxis or com-
bined with antimonials for immuno-chemotherapy [9-
11]. Trials in Brazil, Colombia, Ecuador, and Iran were
presented. The trials conducted in Sudan were presented
by Prof Khalil and Dr Musa and those in Venezuela by Dr
Ulrich (see below).
For prophylaxis, live virulent L. major (leishmanization) is
the best vaccine against human cutaneous leishmaniasis.
It has been used for centuries, much like cow pox, by inoc-
ulating material from exudates of an active lesion into a
covered part of the body. In more recent years in Iran,
Israel and Uzbekistan, leishmanization has been per-
formed by inoculating cultured L. major. Leishmanization
cannot be used on a large scale or in HIV endemic areas.
Since Leishmania undergo biological changes in culture,
lose their infectivity when sub-cultured, and cannot be
lyophilized, they must be kept frozen in liquid nitrogen,
and hence their delivery is impractical. However, if inocu-
lates are standardized and used under special conditions
in non-HIV infected areas, then leishmanization could be
used as a live challenge system in order to assess the effi-
cacy of candidate vaccines [12].
Various killed parasites have been tested for decades with
or without different adjuvants. None of the killed para-
sites has been shown to be sufficiently efficacious as a pro-
phylactic vaccine to be used in control programmes [13].
The parasites tested in this way include L. amazonensis
(tested in Colombia by Velez et al.) [14], and L. mexicana
+ BCG (see below). Autoclaved L. major (ALM) + BCG and
its alum-absorbed preparation (alum-ALM) have been
tested in monkeys using BCG [15]or IL-12 as adjuvants
[16], and in clinical trials against CL in Iran [17,18] and
against VL in Sudan [19] (see below).
First generation vaccines for prophylaxis
Killed L. major + BCG with or without alum in Iran
Initially different methods of killing promastigotes of L.
major were tried; finally autoclaving was used much like
that reported by Convit et al. in Venezuela. The Razi
Serum and Vaccine Institute, Iran, produced the vaccine,
and the Pasteur Institute, Tehran, provided BCG (used for
TB vaccination in the country). Following several safety,
dose escalation and immunogenicity trials in non-
endemic foci of Iran, one injection of 1 mg ALM mixed
with 1/10th of the BCG dose normally used as TB vaccine
was chosen for trials against anthroponotic and zoonotic
CL in Iran [17,18]. A series of double-blind randomized
BCG-controlled trials with 1–3 injections of the vaccine
were conducted. No significant overall difference was seen
between the vaccine group and the control (BCG alone)
group. However, those who had become leishmanin skin
test (LST) positive were found to have significant protec-
tion. Subsequently, ALM was absorbed to alum as Kenney
and colleagues at NIH had shown this preparation to be
far more immunogenic and to produce a strong and long-
lasting Th1 response and protection in mice and monkeys
[16]. The new formulation went through safety, dose-
escalation, immunogenicity and protection studies
against VL in langur monkeys in India [15]. Results were
highly encouraging and indicated clinical development
should continue. Following safety studies in Iran, this
preparation was tested in Sudan (see below). A trial was
also conducted in Iran using one injection of alum-ALM +
BCG in volunteers who then received leishmanization as
challenge infection. This trial did not produce conclusive
results due to low virulence of the live Leishmania stabi-
lates used for leishmanization and low virulence of the
BCG used. Whereas the stabilates had produced 85%–
100% lesions in two previous trials a few years before, the
take rate in this trial was only about 46%. The trial is due
to be repeated with new standardized Leishmania stabi-
lates.
ALM + BCG (without alum) in Sudan
Professor EAG Khalil presented his team's experience with
first generation vaccines. Two preparations – autoclaved
L. major (ALM) + BCG, and alum-ALM + BCG – were
tested as candidates for prophylactic vaccines against VL
[19]. A series of dose escalation, safety and immunogenic-
ity studies were conducted in Iran, where the vaccines
were produced (Razi Institute). The results were satisfac-
tory, and safety and immunogenicity studies were then
conducted using one and two injections of 1 mg + 1/10th
of normal BCG dose used for TB vaccination in healthy
adult volunteers before embarking on a field efficacy trial
in a hyperendemic area (Gedaref state) in Sudan. TheKinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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logic behind using an L. major vaccine against VL is based
on the observation that people who are leishmanin skin
test (LST) positive and come from CL hyperendemic
zones have immunity against VL (suggested from the
results of a prospective epidemiological study) [1]. Sec-
ondly, LST conversion induced by the vaccine seems to be
associated with resistance to leishmaniasis (data from Bra-
zil and Iran), and the killed vaccine induces LST reactivity.
The results of a double-blind, BCG-controlled study
involving 2306 volunteers, randomly allocated to receive
two doses of ALM + BCG or BCG alone with two years of
follow-up, can be summarized [19] as follows:
• Side effects were minimal.
• Cumulative incidence rates of visceral leishmaniasis at
two years were not significantly different between the two
study groups (P = 0.6).
• However, the incidence of VL was significantly lower in
those individuals whose LST became positive (induration
≥ 5 mm) following vaccination compared to non-
responders (7.2%, vs. 12.7%, respectively; P = 0.0003).
These results were encouraging but the vaccine was not
sufficiently immunogenic to be used in control pro-
grammes.
Subsequently, it was shown that absorption of ALM to
alum greatly enhances its immunogenicity and protective
potential against CL in mice and VL in langur monkeys.
Alum-ALM + BCG in Sudan
Two dose-escalating safety and immunogenicity studies
were conducted by Prof Khalil and the Leishmaniasis
Research Group, Sudan. There were 24 and 44 healthy
volunteers in the two trials respectively, and results of the
two studies were essentially the same [20,21]. The vaccine
was safe and side effects were confined to the site of injec-
tion. A single injection of the vaccine at all doses was safe
and immunogenic as measured by LST conversion and
IFN-γ, but there was no significant IL-10 or IL-5 produc-
tion. The vaccine induces a strong Th1 response with no
significant antibody production in almost 100% of volun-
teers by day 60. A single injection produces a stronger
delayed-type hypersensitivity (DTH) response than even
multiple injections of ALM + BCG (no alum). The alum-
ALM preparation without BCG did not induce skin test
conversion indicating that a T-cell adjuvant is required for
DTH response. Based on the results using different doses
in the two trials, 100 µg alum-ALM + BCG was selected as
the most suitable dose to use in efficacy trials. An
extended safety and immunogenicity study was con-
ducted under field conditions; the trial included some
children who are at high risk of VL. The results indicated
that the vaccine was safe and well tolerated under field
conditions. The LST conversion rates were 56%, 50%,
25% and 31% at 6, 12, 18 and 24 months post vaccina-
tion respectively. Conversion rates for the BCG control
group were 4%, 12%, 3% and 13% at the same intervals
respectively. There was no significant antibody rise at fol-
low-up visits (p < 0.05). These are very encouraging
results. Further studies with multiple injections would be
of interest. This vaccine was used for immuno-chemother-
apy of PKDL patients (see below). Prof Khalil summarized
his future plans for this vaccine as follows:
• Conduct phase I/II studies of multiple doses of alum/
ALM + BCG.
• Conduct a prophylactic efficacy trial with alum/ALM +
BCG against VL.
• Conduct an efficacy trial for immuno-chemotherapy of
PKDL (see below).
The experience with killed L. major vaccine can be summa-
rized as follows:
• ALM + BCG is safe, affordable, and induces 8%–17%
LST conversion in populations of endemic foci and 30%–
37% in non-endemic areas. It produces a weak Th1
response but no significant Th2 response.
• Overall, the immunogenicity and protection induced
against CL (zoonotic or anthroponotic) or VL is not suffi-
cient to use the vaccine as a prophylactic in control pro-
grammes. However, LST converted recipients have a
significantly lower incidence of disease.
• No further clinical trials should be considered for this
preparation.
• Addition of alum to ALM + BCG however (alum-ALM +
BCG) makes it highly immunogenic. Alum-ALM + BCG
induces long-lasting LST conversion in almost 100% and
56% of non-endemic and endemic populations respec-
tively.
• A trial on the prophylactic efficacy of the alum-ALM +
BCG compared with leishmanization was inconclusive
and should be repeated with new stabilates of live L.
major.
• Alum-ALM + BCG (multiple injections) should be stud-
ied as a prophylactic vaccine against VL in Sudan.
• Addition of alum-ALM + BCG to standard antimonial
therapy for patients with persistent PKDL significantly
enhances cure (see below).Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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• Alum-ALM with BCG or other adjuvants (CpG) has
induced strong and long immunity and protection in
mice and primates and should be considered as a strong
candidate for human prophylactic studies.
First generation vaccines for treatment
Although the first generation vaccines have not been effi-
cient for prophylaxis, three formulations have shown effi-
cacy alone or when combined with chemotherapy for the
treatment of leishmaniasis. These are:
Killed L. amazonensis in Brazil
Administration of vaccine (Mayrink's vaccine produced
by Biobras) together with daily injection of a reduced dose
of antimonial cured 100% of CL cases in Brazil compared
to only 8% given low-dose antimonial only during the
same period (80 days). The results of this trial by J. Mach-
ado-Pinto et al. (Fig. 1) were used to register the vaccine as
an adjunct to low-dose chemotherapy with antimony
[22].
Killed L. mexicana + BCG in Venezuela
Dr M. Ulrich presented studies on immunotherapy with
autoclaved L. mexicana + BCG which were conducted in
Venezuela. Following the initial trials in the 1990s, more
than 30000 patients have received immunotherapy in
Venezuela. Dr Ulrich outlined the findings from a trial
involving 5341 patients. The dose of BCG was adjusted
according to purified protein derivative (PPD) skin reac-
tion, 0.1 mg for PPD-negative and 0.01 mg for PPD-posi-
tive patients [9]. Patients were injected intradermally in
two sites in the deltoid areas with 0.5 ml of a suspension
containing 6.4 × 108 autoclaved promastigotes of L. mexi-
cana MHOM/VE/84/MEL and freshly resuspended BCG
(Statens Seruminstitut, Denmark). In later practice,
patients were given one or two additional injections at the
discretion of the treating physician. Clinical cure ranged
from 91% to 98% in the different trial sites. Booster injec-
tions significantly shortened the time to cure: three injec-
tions cured 98% of patients within 24 weeks, while only
18% and 38% were cured at this time with a single or dou-
ble injection respectively. More recently, pasteurized
rather than autoclaved L. braziliensis plus BCG was shown
to significantly reduce the time to cure (in 277 patients) as
compared to autoclaved vaccine (56 patients) [10]. Some
preliminary data with 2-D electrophoresis indicate that
proteins are better preserved in pasteurized preparations.
In conclusion:
• Immunotherapy with killed promastigotes plus BCG is
highly effective in treatment of localized cutaneous leish-
maniasis (LCL) in Venezuela.
• Preliminary studies suggest that pasteurized promastig-
otes produce more rapid healing (perhaps due to better
conservation of antigens).
Killed Leishmania major plus alum plus BCG for treatment of PKDL
Dr AM Musa described two observations that led to the
use of the alum-ALM + BCG vaccine as an immunological
stimulus for treatment of patients with persistent PKDL:
• LST positive PKDL patients have a favourable prognosis.
• Alum-ALM + BCG vaccine induces a strong LST reaction.
A series of dose escalation safety studies with single and
multiple injections were conducted using alum-ALM +
BCG in volunteer patients with persistent PKDL who were
under antimony treatment. Together with the data col-
lected on healthy volunteers described by Prof. Khalil,
four doses of 100 µg alum-ALM + BCG were selected for a
proof-of-principle study to show if the addition of vaccine
could reduce the dose of antimonials required for patients
with persistent PKDL (3–4 months of daily injections
with antimonials). This was a hospital-based, blind, rand-
omized, controlled trial. Thirty patients with persistent
PKDL were brought from the endemic area to the hospital
in Khartoum and randomly assigned to receive either 40
injections of 20 mg/kg/day (chemotherapy) or chemo-
therapy + four weekly injections of 100 µg alum-ALM +
BCG (combination). Patients were evaluated at the end of
Patients received daily injections of low dose antimonial +  killed vaccine for 10 days followed by 10 day rest (one cycle) Figure 1
Patients received daily injections of low dose antimonial + 
killed vaccine for 10 days followed by 10 day rest (one cycle). 
After 4 cycles combined treatment cured all patients vs. 8% 
in low chemo alone. Combined treatment significantly 
reduced drug dose, cost and time to cure. The vaccine was 
registered in Brazil. Adopted from Machado-Pinto J. et al. Int. 
J. Dermatol. 41:73-8, 2002. with permission from Oxon Black-
well Pub. http://blackwellpublishing.com.Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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therapy (day 40) to determine the course for further treat-
ment, either continued chemotherapy, or no treatment
but observation or rescue treatment with Ambisome in
failed cases. Patients were again evaluated on day 60, after
which they were discharged.
Combination therapy cured 86.6% of patients at the end
of treatment (day 40), while the remaining 13.4% were
improved and were observed until day 60 but required no
more treatment. Chemotherapy alone cured only 53.3%
at the end of treatment, while 46.7% were not cured at
this time and received continued chemotherapy or rescue
treatment. There were no failures in the group with com-
bined therapy (Fig 2).
A general trend was seen in conversion to LST-positive
reaction or increase in LST with progression to cure. A
mixed Th-1 and Th-2 immune response was observed in
the cytokine patterns, with a trend towards increased IFN-
γ and decreased IL-10. These immunological data must be
considered as an indication rather than proof since the
sample size was small and patient-to-patient variations
large. However, clinical cure rates were significantly differ-
ent in the two groups.
Second generation vaccines
Dr S. Reed, President of IDRI, reviewed the background
and purpose of his institute and its work on diseases of
disadvantaged populations in developing countries. IDRI
was founded in 1993 and focuses on vaccines and diag-
nostics. For leishmaniasis vaccine, IDRI collaborated with
a biotech company (Corixa, now GSK) which had T-cell
adjuvants needed for vaccine development. He explained
that an ideal leishmaniasis vaccine would be one that pro-
duces a Th1 type response to selected 'protective' antigens
and long-term immunity against different species of Leish-
mania, and one that is safe, therapeutic and cost effective.
To this end, Reed and colleagues initiated antigen discov-
ery and realized that not all antigens can protect in mouse
model. From over a dozen antigens, IDRI selected three
protein antigens [23]. Two of these (LSTI1, TSA) were
selected by expression cloning with human or mouse sera
[24-26]. They were also tested by reactivity of T-cells from
recovered/cured leishmaniasis patients and finally vali-
dated in mouse protection studies [25,27,28]. The third
antigen (LeIF) is not protective in mouse models but was
selected on the basis of its unique characteristic of induc-
ing IL-12 (and thereby IFN-γ) and IL-18 in mouse and
human monocytes and fibroblasts [29-31]. LeIF is an
internal adjuvant for Type 1 immune response, and
should be useful for prophylaxis as well as therapeutic
use. Methods for identification of the three selected anti-
gens are shown below.
• LeIF – a ribosomal initiation factor – identified by sero-
logical screening with human sera from healthy, infected,
DTH positive individuals.
• LmSTI1 – a temperature inducible protein – identified
by serological screening with sera from BALB/c mice
infected with L. major (abundant and immunogenic anti-
gens).
• TSA – a thiol-specific antioxidant – identified by serolog-
ical screening with sera from BALB/c mice immunized
with protective leishmanial antigens.
The genes of these three antigens were tandemly linked
and expressed to produce a single protein with the three
subunits [32]. The construct (Leish-111f, shown in Fig 3)
has all the activities of the components and was produced
by Corixa under good manufacturing practice (GMP)
standards for human use.
After testing a dozen adjuvants in protection studies with
Leish-111f in mouse models, monophosphoryl lipid A of
Salmonella minnesota (MPL) was selected. It activates
innate immunity through a TLR-4 receptor, enhances
phagocytosis, up-regulates major histocompatibility com-
plex (MHC) expression, and induces a cascade of
Schematic representation of Leish-111f construct containing  tandemly linked genes of TSA, LmSTI1 and LeIF Figure 3
Schematic representation of Leish-111f construct containing 
tandemly linked genes of TSA, LmSTI1 and LeIF.
Immunochemotherapy of PKDL Figure 2
Immunochemotherapy of PKDL. Patients received either 40 
daily injections of 20 mg/kg/day Sodium Stibogluconate (SSG) 
alone, or SSG plus 4 weekly injections of alum-ALM+BCG. 
Cured = complete disappearance of lesions (not including 
discoloration or scar).Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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cytokines [33]. MPL has been shown to be safe in aqueous
solution and has been used in several human vaccines as
SBAS2 formulation, including in malaria, Epstein-Barr
virus, herpes simplex and hepatitis B vaccines. It has been
given to over 33300 individuals including young adults,
the elderly, and adolescents. In the IDRI Leish-111f vac-
cine, MPL is used as a stable emulsion in squalene (SE) to
enhance its Th1 stimulation over Th2 (seen in aqueous
form). Dr Reed reviewed the pre-clinical studies with indi-
vidual antigens and the final vaccine, Leish-111f + MPL-
SE. Based on data submitted, an investigational new drug
(IND) approval was granted by the US Food and Drug
Administration (FDA) to initiate human phase-1 clinical
studies in the USA and subsequently in Latin America.
Professor R. Badaro presented data on the use of a mixture
of four antigens discovered by IDRI together with GM-CSF
(as adjuvant) on a compassionate basis for treatment of
refractory cases of mucosal leishmaniasis (ML). This work
was done at the Federal University of Bahia, Salvador, Bra-
zil, in collaboration with IDRI and Corixa [34,35]. The
four antigens were the three antigens later used to con-
struct Leish-111f, plus 6H (LmHSP 83), which was chosen
on the basis of its strong human T-cell stimulation. He
first described cytokine patterns in CL patients before and
after cure either by heat or antimonial treatment. He then
reviewed data on the limited trial with Mayrink's vaccine
(killed parasite) and mentioned the concerns about using
material to which ML patients exhibit a strong DTH reac-
tion. He then described a patient who had exhausted all
treatment possibilities without success and was desperate
to the verge of suicide. Following impressive success with
this patient, ten more patients were treated with different
numbers of injections of the vaccine (5 µg each of TSA,
LmSTI1 and Lbhsp83, 10 µg LeIF, plus 50 µg GM-CSF)
and/or received additional antimonial injections. The vac-
cine was safe and well tolerated. Except for expected side
effects related to GM-CSF (flu-like symptoms) and local
irritation at the site of vaccination, no adverse reaction
was observed. All patients were cured and remained with-
out a lesion for 5–8 years of follow-up. This was an open
study, and treatment (vaccine and or chemotherapy) was
given at the discretion of the treating physician.
Some of the patients donated blood samples that were
analyzed for cytokine responses to the four antigens plus
soluble leishmanial antigens (LSA), It is of particular
interest that there was enhancement of IFN-γ and inhibi-
tion of IL-5 to LmSTI1, TSA and LeIF (the three compo-
nents of Leish-111f) after vaccination. There is also
reduction of IL-5 to soluble Leishmania  antigens (SLA)
(whole parasite antigens) after immunization associated
with cure, but there is no change in IFN-γ production (Fig.
4). The IFN-γ level produced by these antigens was already
high prior to vaccination. This is in line with the concept
that cure is accomplished, or at least accompanied by, a
shift to a Th1 type response to leishmanial antigens, and
that IFN-γ production to certain, but not all, antigens is
important for immunity against leishmaniasis. Another
interesting observation was the skin test conversion of
most patients after immunization with the vaccine anti-
gens (not LeIF). Enhanced DTH reaction to leishmanin
post vaccination is not as obvious since most patients
already had a strong (even allergic) reaction to leishmanin
in contrast to their reaction to the recombinant antigens.
Dose-escalating safety and immunogenicity trial in healthy 
volunteers in the US
Dr F Piazza presented the protocols for clinical trials of the
Leish-111f + MPL-SE vaccine in the US. The first clinical
trial was conducted in the State of Washington, USA,
under an IND of the US FDA. The endpoints were the
safety of three injections of 10 µg, 20 µg or 40 µg Leish-
111f mixed with 25 µg MPL-SE in healthy adult volunteers
of both sexes. This was a three cohort, sequential, dose-
escalating, randomized, double-blind, controlled trial.
Each dose cohort consisted of nine volunteers injected
with full vaccine, three with adjuvant alone and three with
saline, so that at the end of the trial there would be nine
volunteers in each group. Following satisfactory safety
results up to day 84 of the first cohort (10 µg dose), the
next cohort (20 µg) would enter the trial. Similarly, the
last cohort of 40 µg was entered when satisfactory safety
outcomes were observed at day 84 of the second cohort.
Follow up was both passive, by a diary kept by the volun-
teers, and active, by physical examination at pre-set inter-
vals and collection of blood specimens. The results are
summarized below:
Cytokine responses of ML patients Figure 4
Cytokine responses of ML patients. Peripheral Blood Mono-
cytes of patients were analysed for production of cytokines in 
vitro when stimulated with different antigens, before and after 
vaccination. Note the increase IFN-γ production to specific 
antigens (TSA, LmSTI1 and LeIF) after vaccination.Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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• 41 (91%) of 45 subjects received all three injections.
• All subjects had at least one adverse event (AE), 80% of
which were mild.
• The most common AEs were limited to the site of injec-
tion (SOI).
• SOI reactions were erythema, induration and pain.
• No subject experienced a severe AE during the study
injection period.
• Four subjects (one in the 20 µg vaccine group, and three
in the 40 µg vaccine group) experienced grade 3 AEs.
One volunteer in cohort 2 who had received adjuvant
alone died of myocardial infarction. After reviewing the
data (by safety monitor) it was decided that the death was
not related to vaccination and the third cohort was
injected with the higher dose. There was no serious AE in
cohort 3. Overall, the vaccine is reactogenic but safe. Fol-
lowing analysis of the safety of the vaccine in healthy indi-
viduals, two safety and immunogenicity trials were
initiated in patients with active CL or ML.
Dose-escalating, safety and immunogenicity trial in 
patients with ML in Peru
Prof A. Llanos-Cuentas described the ongoing double-
blind, three-cohort randomized, placebo-controlled, dose
escalating, safety and immunogenicity trial of Leish-111f
+ MPL-SE in patients with ML in Peru. The cohorts and
injection assignments are shown in Table 1. All patients
received the standard treatment (Sbv) in addition to the
injections indicated in Table 1. As part of safety, lesion
evolution is being assessed to note any possible exacerba-
tion of the disease. As this is a blinded trial, global results
encompassing both arms were presented.
Safety assessment included observation for adverse events
(clinical and laboratory) from days 0–84 and on days 168
and 336. The local and systemic reactions are shown in
Figs. 5 and 6 respectively. The evolution of lesions is
assessed during the 84 days, endpoint clinical response is
assessed on day 84, and subsequent relapse is recorded
through to day 336. Immunological responses are evalu-
ated on days 0 (baseline), 84 and 168. Reactogenicity of
the vaccine is assessed by evaluating tenderness, indura-
tion and erythema at the site of injection and systemic
reactions such as fever, malaise/fatigue, generalized mus-
cle pain, anorexia and headache.
In cohort 1 after the first injection, one patient had
transaminase increase (a grade 4 AE) dose-limiting toxic-
Site of injection reactions following vaccination with Leish- 111f + MPL-SE Figure 5
Site of injection reactions following vaccination with Leish-
111f + MPL-SE.
Table 1: Treatment Groups in Patients with Mucosal Leishmaniasis (Peru)
Cohort N Treatment Timing of Treatment
Study Injections Pentavalent Antimony 
(Sb5+)
# 1 12
4
5 µg Leish-111f in 25 µg 
MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SSC1
# 2* 12
4
10 µg Leish-111f in 25 µg 
MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SSC1
# 3** 12
4
20 µg Leish-111f in 25 µg 
MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SSC1
1SSC = Standard single cycle: 28 days of pentavalent antimony (20 mg/kg IV once daily) starting on Day 0.
Sequential enrollment of cohorts: * = after Day 84 of cohort 1; ** = after Day 84 of cohort 2.Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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ity (DLT) attributed to antimony treatment and unrelated
to study injection and was given no further injections. In
cohort 1 at one year follow-up of final study visit, 5
patients were considered as failed and received amphoter-
icin B (AmphB) rescue treatment; three patients were
cured, and two were rescued. In cohort 2, all 16 patients
received three study injections; at the 6-month follow-up
no significant AE has been observed. Four patients failed
and received AmphB rescue treatment, three were cured
and one was under treatment. In cohort 3, 15 of 16
patients received all three study injections. One had a
grade 4 AE/DLT (increased transaminases, attributed to
antimony treatment and unrelated to study injection)
after the first study injection and was not given further
injections. At the time this presentation 15 had completed
the day-84 visit. Three patients failed and had to be res-
cued with AmphB.
Dose-escalating, safety and immunogenicity trial in 
patients with CL in Brazil
Dr Piazza presented this trial as Prof E. Nascimento (prin-
ciple investigator of the Brazil trial) could not be present.
The overall design of the study is similar to that above, in
healthy individuals in the US, except for the lower dose
range (5 µg, 10 µg and 20 µg instead of 10 µg, 20 µg, and
40 µg in healthy adults). The cohorts and injection assign-
ments are shown in Table 2.
The status of this ongoing double-blind study at the time
of presentation was summarized as follows:
No patient is doing worse and most patients appear to be
doing better than anticipated with antimony treatment
alone. The study remains blinded and immunological
evaluation is in progress.
The ML trial in Peru and the CL trial in Brazil were both
completed successfully in 2006. In both trials the vaccine
was shown to be safe and immunogenic. Final reports and
manuscripts are in preparation.
Immune responses of healthy volunteers to Leish-111f + 
MPL-SE
Dr R Coler described clinical immune monitoring of
phase-1 clinical trials of Leish-111f + MPL-SE (in USA,
Peru and Brazil, the latter two still coded) under condi-
tions of good clinical laboratory practices. In the US trial,
90 normal serum donor samples and 30 normal PBMC
Systemic Reactogenicity following vaccination with Leish-111f  + MPL-SE Figure 6
Systemic Reactogenicity following vaccination with Leish-111f 
+ MPL-SE.
Table 2: Treatment Groups in Patients with Cutaneous Leishmaniasis (Brazil)
Cohort N Treatment Timing of Treatment
Study Injections Pentavalent Antimony 
(Sb5+)
# 1 9
3
3
5 µg Leish-111f in 25 µg 
MPL-SE + Sb5+
25 µg MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SMC1
# 2* 9
3
3
10 µg Leish-111f in 25 µg 
MPL-SE + Sb5+
25 µg MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SMC1
# 3** 9
32
3
20 µg Leish-111f in 25 µg 
MPL-SE + Sb5+
25 µg MPL-SE + Sb5+
Placebo (saline) + Sb5+
Day 0, Day 28 and Day 56 SMC1
1SMC = Standard multiple cycles: 10 days of pentavalent antimony (10 mg/kg IM or IV once daily) starting on Day 0, followed by 11 days of no 
antimony. Cycles are repeated until cure is achieved.
2Only 2 patients were randomized to adjuvant in the third cohort (inability to recruit 15 patients). Sequential enrollment of cohorts: * = after Day 
84 of cohort 1; ** = after Day 84 of cohort 2.Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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donor samples were run together with samples from vol-
unteers in the trial. All assays were qualified. Tests
included antibody by ELISA, T-cell proliferation, and IFN-
γ and IL-5 measurement. Criteria for plate acceptance, and
cut-off values for positive and negative responses, were
established. Responses against Leish-111f and each of its
components (LmSTI1, TSA, LeIF) were determined. Blood
samples were collected from volunteers on days 0 (base-
line), 28 (prior to first booster), 56 (prior to second
booster), 84 (4 weeks post last study injection), 168 (4
months post last study injection, at the 6-month follow-
up) and 336 (1-year follow-up).
From the trial on healthy volunteers in the US (see above),
results can be summarized as follows:
• High IgG antibodies (dose related) to Leish-111f were
seen which were generally dose related and increased with
booster injections.
• All volunteers produced antibody to Leish-111f by day
56 and remained positive on day 84.
• Antibodies to the three components of Leish-111f were
similarly detected (LmSTI1>TSA>LeIF), although at lower
titres than the whole antigen.
• For cellular responses, unseparated PBMC were tested in
a standard five-day lymphoproliferative assay with differ-
ent doses of Leish-111f, the three components, phytohe-
magglutinin A (PHA), and several control proteins.
Supernatants of cultures were assayed by ELISA for IFN-γ
and IL-5.
By day 84, 100% of volunteers in the first two cohorts
who had received 10 µg or 20 µg Leish-111f had a positive
lymphoproliferative response. In contrast, only 75% in
cohort 3 (highest vaccine dose, 40 µg Leish-111f) had pos-
itive stimulation indices on day 84, although 100% were
positive on day 56 when 88% and 78% had positive stim-
ulation index (SI) in cohorts 1 and 2 respectively. In the
classical cytokine assay, 12/26 and 20/26 volunteers were
positive for IFN-γ and IL-5 respectively, when cells were
stimulated with Leish-111f. The same but weaker
responses were seen with antigen components. The mag-
nitude of responses were Leish-111f>LSTI1>TSA>LeIF.
Higher doses of the vaccine antigen did not seem to
induce higher cytokine responses. Indeed, there was a
decrease in responders at the highest dose. However, IFN-
γ responses increased after the first booster injections; the
increase was smaller after the second booster.
To study longevity of immune response, blood samples
were collected and assayed six months (day 168) and one
year (day 336) after vaccination. IgG antibodies were
present in 100% of volunteers by day 168, and 89%–
100% by day 336 in different cohorts, indicating a long-
lasting B-cell response without further exposure to anti-
gens. On day 168, 100%, 100% and 75% of volunteers
had positive proliferative indices in cohorts 1 (10 µg), 2
(20  µg) and 3 (40 µg) respectively. By day 336, the
responses were 75%, 56% and 62% for the same cohorts.
For IFN-γ, there were 25%, 22% and 22% responders on
day 168 in cohorts 1, 2 and 3 respectively; and 50%, 11%
and 25% responders on day336 in the same cohorts. For
IL-5, there were 62%, 78% and 75% responders on day
168, and 62%, 44% and 88% responders on day336 in
cohorts 1, 2 and 3 respectively. These data indicate that
three injections of the vaccine induce humoral and cellu-
Schematic representation of whole blood culture for assays  of cytokine Figure 8
Schematic representation of whole blood culture for assays 
of cytokine.
Cytometric bead array evaluation of supernatants for differ- ent cytokines Figure 7
Cytometric bead array evaluation of supernatants for differ-
ent cytokines.Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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lar responses that remain positive for up to one year post
vaccination in some volunteers.
Using the cytometric bead array system for several
cytokines on the same supernatants from day-84 samples,
the predominance of the IFN-γ response over IL-5 and
other cytokines was demonstrated (Fig. 7). In general,
there was considerable variation in the magnitude of
cytokine responses amongst volunteers so, given the small
sample size, these data must be regarded as trends rather
than statistically significant differences.
Dr Coler also presented some data on antibody responses
in the Peru study, though these data are coded. There were
positive, albeit weak, responses to Leish-111f in some
samples. For the Peru and Brazil studies, a whole blood
culture technique for cytokine production was described
(Fig. 8).
Dr Coler outlined her future plans using whole cell cul-
tures and cytometic bead array (CBA) as follows:
• Assess the duration of B and T-cell responses, in particu-
lar of memory T cells upon re-exposure to leishmanial
antigens.
• Measure classes and subclasses of antibodies (IgG1,
IgG4, other Igs, IgE).
• Test the available supernatants of cultures for additional
cytokines using the CBA method.
Recommendations
Treatment of PKDL
1. Based on the highly significant results of the hospital-
based trial with alum-ALM + BCG in Sudan, an expanded
trial under field conditions is recommended. Before the
trial, availability of the vaccine, and its production under
good manufacturing practices (GMP) and hence quality
control, must be assured.
2. Considering the safety profile of Leish-111f + MPL-SE
in healthy and active cases, the product profile documents
generated by IDRI should be submitted to the Sudanese
Authorities for obtaining clearance to conduct a safety-
immunogenicity trial in patients with PKDL. Only one
dose (three injections of 10 µg Leish-111f) should be con-
sidered and the protocol previously developed by TDR
and IDRI should be updated accordingly.
3. Considering the immuno-stimulatory activities of
sodium stibogluconate (SGG), the initial trials should use
SSG. Subsequently, other agents (Miltefosine, Aminosi-
dine, Ambisome) should be considered.
4. Should combination therapy be successful, the thera-
peutic efficacy of vaccines (alone) should be considered.
5. The ultimate goal is to prevent VL. Prophylactic trials
with the vaccines should be planned if the vaccines are
shown to be effective for PKDL therapy.
Prevention of PKDL
This is one objective of using Leish-111f + MPL-SE:
1. Timing of vaccination during chemotherapy is crucial
considering the immunological and haematological/bio-
chemical status of most VL patients at the start of treat-
ment. It is important to follow the responses (including
extensive cytokine profiles) of VL patients during chemo-
therapy in order to decide when to introduce immuno-
therapy.
2. Some VL patients develop PKDL while under treatment
with SSG. A close immunological analysis of these
patients might reveal markers associated with high risk of
PKDL development.
Treatment of VL
Shortening the time of VL treatment, reducing the dose of
medications, and preventing resistance are part of the sec-
ond objective for use of Leish-111f + MPL-SE:
1. A single dose of Ambisome has been reported to cure
over 90% of cases of VL in India. Addition of a vaccine to
the treatment is recommended for preventing resistance
to Ambisome. Time of introducing the vaccine is impor-
tant (see objective 1 on prevention of PKDL). Resistance
to any drug is bound to happen when single drug therapy
is used.
2. It is important to prevent resistance to Miltefosine and
Aminosidine, two valuable drugs that are being consid-
ered for leishmaniasis control on the Indian sub-conti-
nent. Safety trials of combination therapy should be
considered with urgency. Again the time to inject the vac-
cine is important (see objective 1 on prevention of PKDL).
3. Once combined therapy is shown to be advantageous,
and with the information gained through immunological
studies of VL patients under therapy, immunotherapy
alone can be considered. The ethical aspects should
receive particular attention.
4. It is highly desirable to reduce the treatment period of
VL in Sudan. Shorter periods of SSG (15 days instead of
30) with or without a vaccine should be studied.Kinetoplastid Biology and Disease 2007, 6:7 http://www.kinetoplastids.com/content/6/1/7
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